Secondary Logo

Journal Logo

AAPA Members can view Full text articles for FREE. Not a Member? Join today!

Institutional members access full text with Ovid®

What is the role of triple inhaled therapy in COPD?

Petite, Sarah E. PharmD, BCPS

Journal of the American Academy of PAs: October 2019 - Volume 32 - Issue 10 - p 44–45
doi: 10.1097/01.JAA.0000580568.79593.55
Pharmacology Consult

ABSTRACT Triple inhaled therapy for maintenance of chronic obstructive pulmonary disease (COPD) consists of an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting 2-agonist">beta2-agonist. Recent clinical studies evaluating triple therapy found a reduction in COPD exacerbations compared with other combination therapies. This article discusses the role of triple therapy in treating patients with COPD.

Sarah E. Petite is an assistant professor of pharmacy practice at the University of Toledo (Ohio) College of Pharmacy and Pharmaceutical Sciences. The author has disclosed no potential conflicts of interest, financial or otherwise.

Mary Lou Brubaker, PharmD, PA-C, department editor

Copyright © 2019 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website